Who are Atripla (r)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TDF/3TC/EFV or DTG or NVP, Tenofovir, lamivudine and efavirenz, DOR/DTG/3TC, Atripla or Stribild, efavirenz + emtricitabina + tenofovir, Doravirine, Tenofovir, Lamivudine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atripla-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Atripla (r) — Competitive Intelligence Brief

Atripla (r) (Atripla (r)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NNRTI + NRTI + NtRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Atripla (r) (Atripla (r)) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Atripla is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication by blocking reverse transcriptase and integrase enzymes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Atripla (r) TARGET	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
Tenofovir, lamivudine and efavirenz	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
efavirenz + emtricitabina + tenofovir	efavirenz + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Doravirine, Tenofovir, Lamivudine	Doravirine, Tenofovir, Lamivudine	Merck Sharp & Dohme LLC	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NNRTI + NRTI + NtRTI) class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
Thomas Jefferson University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atripla (r) — Competitive Intelligence Brief. https://druglandscape.com/ci/atripla-r. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab